Drug escalation testing (from 0.625-10 nM) clearly showed a progressive decline in intracellular NAD levels, already highly significant at the lowest dose and at 24 hours ( supplemental Figures 4 A and 5 A for OT-82 and FK866, respectively).
← all excerpts
A molecular circuit linking the BCR to the NAD biosynthetic enzyme NAMPT is an actionable target in Richter syndrome.
1
—
—